Press Releases

Press Releases

  • May 6, 2024
    Aileron Therapeutics to Present at Two Upcoming Investor Conferences
  • May 3, 2024
    Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
  • May 1, 2024
    Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
  • May 1, 2024
    Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
  • April 15, 2024
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
  • March 12, 2024
    Aileron Therapeutics Announces CEO Transition
  • February 15, 2024
    Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
  • February 1, 2024
    Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
  • October 31, 2023
    Aileron Therapeutics Announces Acquisition of Lung Therapeutics
  • February 21, 2023
    Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives